Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients with Early Parkinson's Disease.

Autor: Marras C; The Edmond J Safra Program in Parkinson's Research and the Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada., Mills KA; Johns Hopkins Parkinson's Disease and Movement Disorders Center, Johns Hopkins University, Baltimore, Maryland, USA., Eberly S; Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA., Oakes D; Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA., Chou KL; Departments of Neurology and Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan, USA., Halverson M; University of Utah, Salt Lake City, Utah, USA., Parashos SA; Struthers Parkinson's Center, Park Nicollet Health Services, Golden Valley, Minnesota, USA., Tarolli CG; Department of Neurology, University of Rochester, Rochester, New York, USA., Lai JS; Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Nowinsky CJ; Departments of Medical Social Sciences and Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Suchowersky O; Department of Medicine (Neurology), Medical Genetics and Pediatrics, University of Alberta, Edmonton, Alberta, Canada., Farbman ES; Department of Neurology, Roseman University of Health Sciences, Las Vegas, Nevada, USA., Shulman LM; Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Simuni T; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Jazyk: angličtina
Zdroj: Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2021 Aug; Vol. 36 (8), pp. 1979-1983. Date of Electronic Publication: 2021 May 13.
DOI: 10.1002/mds.28641
Abstrakt: Background: The Quality of Life in Neurological Disorders (Neuro-QoL) is a publicly available health-related quality-of-life measurement system.
Objective: The aim of this study was to evaluate the utility of Neuro-QoL item banks as outcome measures for clinical trials in Parkinson's disease.
Methods: An analysis of Neuro-QoL responsiveness to change and construct validity was performed in a multicenter clinical trial cohort.
Results: Among 310 participants over 3 years, changes in five of eight Neuro-QoL domains were significant (P < 0.05) but very modest. The largest effect sizes were seen in the cognition and mobility domains (0.35-0.39). The largest effect size for change over the year in which levodopa was initiated was -0.19 for lower extremity function-mobility. For a similarly designed clinical trial, estimated sample size required to demonstrate a 50% reduction in worsening ranged from 420 to more than 1000 participants per group.
Conclusions: More sensitive tools will be required to serve as an outcome measure in early Parkinson's disease. © 2021 International Parkinson and Movement Disorder Society.
(© 2021 International Parkinson and Movement Disorder Society.)
Databáze: MEDLINE
Externí odkaz: